Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $18.96 million. The enterprise value is -$5.77 million.
| Market Cap | 18.96M |
| Enterprise Value | -5.77M |
Important Dates
The next estimated earnings date is Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 8.24 million shares outstanding. The number of shares has increased by 8.67% in one year.
| Current Share Class | 8.24M |
| Shares Outstanding | 8.24M |
| Shares Change (YoY) | +8.67% |
| Shares Change (QoQ) | +19.61% |
| Owned by Insiders (%) | 4.53% |
| Owned by Institutions (%) | 26.23% |
| Float | 6.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.47 |
| Forward PS | 28.86 |
| PB Ratio | 0.75 |
| P/TBV Ratio | 0.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.99
| Current Ratio | 9.99 |
| Quick Ratio | 9.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -54.41% and return on invested capital (ROIC) is -36.08%.
| Return on Equity (ROE) | -54.41% |
| Return on Assets (ROA) | -33.07% |
| Return on Invested Capital (ROIC) | -36.08% |
| Return on Capital Employed (ROCE) | -53.13% |
| Weighted Average Cost of Capital (WACC) | 6.80% |
| Revenue Per Employee | $143,015 |
| Profits Per Employee | -$816,752 |
| Employee Count | 14 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.16% in the last 52 weeks. The beta is 0.46, so Lipocine's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -26.16% |
| 50-Day Moving Average | 2.28 |
| 200-Day Moving Average | 4.69 |
| Relative Strength Index (RSI) | 47.42 |
| Average Volume (20 Days) | 107,907 |
Short Selling Information
The latest short interest is 90,238, so 1.09% of the outstanding shares have been sold short.
| Short Interest | 90,238 |
| Short Previous Month | 102,133 |
| Short % of Shares Out | 1.09% |
| Short % of Float | 1.31% |
| Short Ratio (days to cover) | 0.89 |
Income Statement
In the last 12 months, Lipocine had revenue of $2.00 million and -$11.43 million in losses. Loss per share was -$1.97.
| Revenue | 2.00M |
| Gross Profit | 2.00M |
| Operating Income | -12.13M |
| Pretax Income | -11.43M |
| Net Income | -11.43M |
| EBITDA | -12.07M |
| EBIT | -12.13M |
| Loss Per Share | -$1.97 |
Balance Sheet
The company has $24.73 million in cash and n/a in debt, with a net cash position of $24.73 million or $3.00 per share.
| Cash & Cash Equivalents | 24.73M |
| Total Debt | n/a |
| Net Cash | 24.73M |
| Net Cash Per Share | $3.00 |
| Equity (Book Value) | 22.83M |
| Book Value Per Share | 3.05 |
| Working Capital | 22.72M |
Cash Flow
| Operating Cash Flow | -10.05M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 60,026 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.05M |
| FCF Per Share | -$1.22 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -605.86% |
| Pretax Margin | -571.10% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.67% |
| Shareholder Yield | -8.67% |
| Earnings Yield | -60.30% |
| FCF Yield | -52.99% |
Analyst Forecast
The average price target for Lipocine is $6.00, which is 160.87% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 160.87% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | -15.33% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 1:17.
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
Lipocine has an Altman Z-Score of -6.07 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.07 |
| Piotroski F-Score | 1 |